Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NHS England/NICE Consultation Could Spell Market Access Complications

Executive Summary

Companies with innovative and expensive drugs may face additional hurdles to get their products to the market in England, according to a consultation from NICE, England's health technology appraisal institute, and NHS England.


Related Content

UK Report Casts Doubt Over Use Of QALYs When Appraising Ultra Orphans
BIA Says NHS Funding Changes Would Jeopardize Life Science Sector, As UK PM Announces ‘Hard’ Brexit


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts